4-Hydroxy-7-nitro-chinol-2-yl-carbonsaeure | 36308-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Hydroxy-7-nitro-chinol-2-yl-carbonsaeure
• 英文别名: 7-nitro-4-hydroxy-2-carboxyquinoline；4-hydroxyl-7-nitryl-2-quinoline carboxylic acid；7-nitro-4-oxo-1H-quinoline-2-carboxylic acid
• CAS: 36308-78-8
• 化学式: C₁₀H₆N₂O₅
• 分子量: 234.168
• InChiKey: IQRAMWTVXIQPPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES DE 2-AMINOCARBONYL-QUINOLINE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE DIPHOSPHATE DES PLAQUETTES
  申请人：SCHERING AG

  公开号：WO2004052366A1

  公开（公告）日：2004-06-24

  Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  式（I）中的化合物，其中m、n、R1、R2、R3、R4和R6如本文所述，可用作血小板腺苷二磷酸酶抑制剂。本文还描述了含有这些化合物的药物组合物、使用这些化合物作为抗血栓剂的方法以及合成这些化合物的方法。
• Heterocyclic Substituted Acardite Derivate and Application Thereof
  申请人：Zhang Aihua

  公开号：US20120053192A1

  公开（公告）日：2012-03-01

  This present invention discloses a heterocyclic substituted acardite derivate and application thereof, namely compounds in the general formula (1) or the general formula (2) or pharmaceutically acceptable salts thereof, wherein A is monosubstituted or polysubstituted quinoline, isoquinoline, quinazoline, pyrrole or pyrimidine, and the substituent is halogen, C 1-5 alkyl, C 1-5 haloalkyl, C 1-5 alkoxy, C 1-5 haloalkoxy, C 1-5 alkylamino, C 1-5 haloalkylamino, amino or nitryl; R 1 is C 1-5 alkyl; R 2 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; and R 3 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy. The compound of the present invention and the pharmaceutically acceptable salt thereof can be used for treating tumor or leukemia.

  本发明公开了一种杂环取代阿卡尔地衍生物及其应用，即通式（1）或通式（2）中的化合物或其药学上可接受的盐，其中A是单取代或多取代的喹啉、异喹啉、喹啉、吡咯或嘧啶，取代基是卤素、C1-5烷基、C1-5卤代烷基、C1-5烷氧基、C1-5卤代烷氧基、C1-5烷基氨基、C1-5卤代烷基氨基、氨基或硝基；R1是C1-5烷基；R2是氢、卤素、烷基、烷氧基、卤代烷基或卤代烷氧基中的一个或多个；R3是氢、卤素、烷基、烷氧基、卤代烷基或卤代烷氧基中的一个或多个。本发明的化合物及其药学上可接受的盐可用于治疗肿瘤或白血病。
• Platelet adenosine diphosphate receptor antagonists
  申请人：Schering Aktiengesellschaft

  公开号：US20030060474A1

  公开（公告）日：2003-03-27

  Compounds of the following formula (I): 1 where a, b, R 1 , R 2 , R 4 and R 6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  以下公式（I）的化合物：其中a、b、R1、R2、R4和R6如下所述，可用作抑制血小板腺苷二磷酸的药物。本文还描述了含有这些化合物的药物组合物，使用这些化合物作为抗血栓药物的方法以及合成这些化合物的过程。
• Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0303387A1

  公开（公告）日：1989-02-15

  4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-­aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-­acidic group or a group convertible thereto in vivo, other than carboxy or C₁₋₆ alkoxycarbonyl, are novel compounds, as also are compounds of formula II wherein R² represents carboxy or a group convertible thereto in vivo, R⁶ is hydrogen and R⁵ and R⁷ represent C₁₋₆ alkyl or halogen, provided that R⁵ and R⁷ are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.

  具有 2-酸性基团或体内可转化基团的 4-氧代-1,4-二氢喹啉化合物及其药学上可接受的盐类是 N-甲基-D-天冬氨酸（NMDA）受体的强效特异性拮抗剂，因此可用于治疗神经退行性疾病。除羧基或 C₁₋₆ 烷氧羰基外，具有 2-酸性基团或在体内可转化的基团的 4-氧代-1,4-二氢喹啉化合物是新型化合物，如式 II 所示的化合物 其中 R² 代表羧基或体内可转化为羧基的基团，R⁶ 是氢，R⁵ 和 R⁷ 代表 C₁₋₆ 烷基或卤素，但 R⁵ 和 R⁷ 不能同时为氯或同时为溴。
• HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF
  申请人：Nanjing Luyesike Pharmaceutical Co., Ltd.

  公开号：EP2428506B1

  公开（公告）日：2014-03-05